Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 258

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 258
---
 February 2018, the Company                                                                                                      
 entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Service Agreement” and “Baxter”,                 
 respectively), pursuant to which the Company agreed to purchase certain services from the third party in connection with GelrinC.  
 In April 2022, we amended the Baxter Services Agreement to replace Teva Medical Marketing Ltd. (“Teva”) as the supplier            
 of Tisseel under the Supply Agreement for GelrinC with Baxter Healthcare Distribution Ltd. as Teva ceased to distribute Tisseel in 
 the territory of Israel.                                                                                                           |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support.

<div align='center'>F-12</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

In consideration for receiving such support,
the Company pays Baxter $60 per year until the Company will receive an approval from the U.S. Food and Drug Administration (“FDA”)
to market GelrinC in the United States. Following FDA approval to market GelrinC in the United States, the Company shall pay Baxter $200
per year during the term of this Services Agreement; however, the year the Company will receive an FDA approval to market GelrinC in
the United States, the Company must pay the remining $140 balance for that year within 30 days after receiving such approval. The Company
incurred expenses under the Services Agreement of $20 for the six months ended June 30, 2024 and 2023.

| 3. | In July 2008, the Company                                                                                                                 
 entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company     
 agreed to purchase Tisseel VHSD fibrin sealant Kit ( “Tisseel”), from Teva, with Teva being Baxter’s exclusive                            
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500